suck pdf from google scholar
unlimited free pdf from europmc18790742    free
PDF from PMC    free
html from PMC    free
PDF vom PMID18790742 :   free
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text


  • DeepDyve
  • Pubget Overpricing


  • lüll
  • Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials
  • Rodon J; DeSantos V; Ferry RJ Jr; Kurzrock R
  • Mol Cancer Ther 2008[Sep]; 7 (9): 2575-88
  • The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate. The understanding of the roles of hormones in cancer and the growth hormone-IGF-IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling associated with this axis. The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis. Nowadays, >25 molecules with the same goal are at different stages of development. Here, we review the clinical and preclinical experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations. We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment.
  • |*Clinical Trials as Topic[MESH]
  • |*Drug Design[MESH]
  • |Animals[MESH]
  • |Antibodies, Monoclonal/pharmacology[MESH]
  • |Antineoplastic Agents/adverse effects/*pharmacology[MESH]
  • |Drug Resistance, Neoplasm/drug effects[MESH]
  • |Humans[MESH]
  • |Receptor, IGF Type 1/*antagonists & inhibitors[MESH]





  • *{{pmid18790742}}
    *<b>[http://www.kidney.de/mlpefetch.php?search=18790742 Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials ]</b> Mol Cancer Ther 2008; 7(9) ; 2575-88 Rodon J; DeSantos V; Ferry RJ Jr; Kurzrock R

        *18790742*

    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren

    Mol Cancer Ther

    2575 9.7 2008